Emcure Pharmaceuticals Ltd vs Ipca Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Emcure Pharmaceuticals Ltd is ₹ 1691 as of 05 May 15:30 . The P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 years The Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 years The revenue of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 2484 crore as compare to the Dec '25 revenue of ₹ 2365 crore. This represent the growth of 5.02% The revenue of Ipca Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 2430 crore. This represent the decline of -100% The ebitda of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 493.84 crore as compare to the Dec '25 ebitda of ₹ 456.45 crore. This represent the growth of 8.19% The ebitda of Ipca Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 571.19 crore. This represent the decline of -100% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 243.74 crore over 8 quarters. This represents a CAGR of 26.39% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 yearsThe Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 years .

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

FAQs for the comparison of Emcure Pharmaceuticals Ltd and Ipca Laboratories Ltd

Which company has a larger market capitalization, Emcure Pharmaceuticals Ltd or Ipca Laboratories Ltd?

Market cap of Emcure Pharmaceuticals Ltd is 33,844 Cr while Market cap of Ipca Laboratories Ltd is 38,831 Cr

What are the key factors driving the stock performance of Emcure Pharmaceuticals Ltd and Ipca Laboratories Ltd?

The stock performance of Emcure Pharmaceuticals Ltd and Ipca Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Emcure Pharmaceuticals Ltd and Ipca Laboratories Ltd?

As of May 5, 2026, the Emcure Pharmaceuticals Ltd stock price is INR ₹1785.15. On the other hand, Ipca Laboratories Ltd stock price is INR ₹1530.6.

How do dividend payouts of Emcure Pharmaceuticals Ltd and Ipca Laboratories Ltd compare?

To compare the dividend payouts of Emcure Pharmaceuticals Ltd and Ipca Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.